Country: দক্ষিণ আফ্রিকা
ভাষা: ইংরেজি
সূত্র: South African Health Products Regulatory Authority (SAHPRA)
Adcock
ACTOSPECT COUGH LINCTUS SCHEDULING STATUS: Not scheduled PROPRIETARY NAME (and dosage form): ACTOSPECT COUGH LINCTUS (SYRUP) COMPOSITION: Each 10 mL contains: Guaifenesin 200 mg Nipastat (Preservative) 0,02 % m/v In a sugar-free, alcohol-free, mentholated, honey-flavoured base. PHARMACOLOGICAL CLASSIFICATION: A 10.1 Antitussives and expectorants. PHARMACOLOGICAL ACTION: Guaifenesin has expectorant properties. INDICATIONS: Alleviation of cough. CONTRA-INDICATIONS: Hypersensitivity to any of the ingredients. Pregnancy. Porphyria. WARNINGS: Guaifenesin should not be taken for persistent cough such as occurs with smoking, asthma, emphysema or where cough is accompanied by excessive secretions except under the advice and supervision of a doctor. A persistent cough may be a sign of a serious condition. If cough persists for more than one week, tends to recur or is accompanied by high fever, rash or persistent headache, consult a doctor. Guaifenesin should not be given to children under 2 years unless recommended by a doctor. DOSAGE AND DIRECTIONS FOR USE: Adults, adolescents and geriatrics: 10 mL - 20 mL (2 to 4 medicine measures) every 4 hours. Children: 6 - 12 years: 5 mL - 10 mL (1 to 2 medicine measures) every 4 hours. 2 - 6 years: 2,5 mL - 5 mL (½ to 1 medicine measure) every 4 hours. SIDE-EFFECTS AND SPECIAL PRECAUTIONS: Gastro-intestinal discomfort (including diarrhoea, nausea, vomiting and stomach pains). Dizziness, headache, skin rash and urticaria occurs less frequently. Precautions: Consult a doctor if cough persists after medication has been used for 7 days or if fever, skin rash, continuing headache, or sore throat is present with cough. Interactions: Guaifenesin interferes with urine tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA). KNOWN SYMPTOMS OF সম্পূর্ণ নথি পড়ুন